1 Clinic for Neurology, RHÖN Clinics, Campus Bad Neustadt, Bad Neustadt, Germany;
2 Department of Anatomy and Neuroscience, School of Medicine, University of Osijek, Osijek, Croatia;
3 Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China;
4 Department of Master's Program in Neurology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China;
5 Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China
Biomarkers in Alzheimer's disease
Rajka M. Liscic1,2, Yuanhan Yang3,4,5
1 Clinic for Neurology, RHÖN Clinics, Campus Bad Neustadt, Bad Neustadt, Germany;
2 Department of Anatomy and Neuroscience, School of Medicine, University of Osijek, Osijek, Croatia;
3 Department of Neurology, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China;
4 Department of Master's Program in Neurology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, China;
5 Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China
摘要 Alzheimer's disease (AD) so far did not have promising treatment. The accurate and early diagnosis is still the important issue. For these purpose, biomarkers related to diagnosis, clinical course, and other aims have been proposed and reported. Meanwhile, along with the ongoing researches for AD, biomarkers with their own aims are also on the way.
Abstract: Alzheimer's disease (AD) so far did not have promising treatment. The accurate and early diagnosis is still the important issue. For these purpose, biomarkers related to diagnosis, clinical course, and other aims have been proposed and reported. Meanwhile, along with the ongoing researches for AD, biomarkers with their own aims are also on the way.
[1] Lee Y. The recent decline in prevalence of dementia in developed countries: Implications for prevention in the Republic of Korea. J Korean Med Sci 2014, 29(7): 913-918.
[2] Lublin AL, Gandy S. Amyloid-beta oligomers: Possible roles as key neurotoxins in Alzheimer's disease. Mt Sinai J Med 2010, 77(1): 43-49.
[3] Maggio JE, Stimson ER, Ghilardi JR, Allen CJ, Dahl CE, Whitcomb DC, Vigna SR, Vinters HV, Labenski ME, Mantyh PW. Reversible in vitro growth of Alzheimer disease betaamyloid plaques by deposition of labeled amyloid peptide. Proc Natl Acad Sci USA 1992, 89(12): 5462-5466.
[4] Lee HJ, Zhang Y, Zhu C, Duff K, Pardridge WM. Imaging brain amyloid of Alzheimer disease in vivo in transgenic mice with an Abeta peptide radiopharmaceutical. J Cereb Blood Flow Metab 2002, 22(2): 223-231.
[5] Villemagne VL, Ong K, Mulligan RS, Holl G, Pejoska S, Jones G, O'Keefe G, Ackerman U, Tochon-Danguy H, Chan JG, Reininger CB, Fels L, Putz B, Rohde B, Masters CL, Rowe CC. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med 2011, 52(8): 1210-1217.
2016, Vol. 2 
